The development of inhibitors is the most serious complication in the use of coagulation factor concentrates in hemophilia management. As patients with inhibitors remain a major therapeutic challenge, bypassing agents such as factor eight inhibitor bypass activity (FEIBA) are the only agents available for the treatment of bleeds in inhibitor patients. To further elaborate on this issue, Takeda and Docplexus have organized an interactive LIVE webinar on 3rd June 2020, Wednesday, 6 PM.

Join the expert, Brig (Dr) Satyaranjan Das who will be discussing his insights on the management strategy of hemophilia, by detailing on “Inhibitor Management with FEIBA.” C-APROM/IN//0574   Disclaimer This information is solely intended for the use of Registered Medical Practitioner and Hospital only. This information should not be used or shared or distributed to any other person / party and should be…